Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

USCOM LIMITED Investor Presentation 2015

Sep 3, 2015

65979_rns_2015-09-03_f180f8c7-c348-434d-83ef-855ffde9ae3d.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

==> picture [842 x 118] intentionally omitted <==

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the accompanying Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

Uscom

Products generate profit

High growth (+50% pa), innovative medical device company Outstanding science Key cardiovascular pulmonary markets and multiple products De-risked technology Poised for strategic growth with recent acquisitions Valuable IP with high margins (75+%) Unrecognised value - $15m market cap US growth from new products and reimbursement Fundamentals to drive value

4

==> picture [741 x 417] intentionally omitted <==

Uscom vision

Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards

“A milestone driven global medical device company with real products, real revenue, real growth and an aggressive growth strategy”

==> picture [397 x 51] intentionally omitted <==

==> picture [219 x 97] intentionally omitted <==

Current Business

  • Premium noninvasive cardiovascular and pulmonary monitoring devices

  • Addressing the growing threat of superbugs, heart failure, hypertension and asthma

  • Validated, clinically accepted, cost and life saving devices with critical applications

  • IP protected with regulatory approvals

  • Uscom BP+ for market 2016 - $7m over 5years Chinese contract in place

  • +50% revenue growth in Asia and Europe, with US market ahead

Financials

  • Corporate Board & Management Financials

  • � ASX listed (UCM) � Rob Phillips, Chairman & CEO � Sales +59% 2015 � Headquartered in Sydney � Sheena Jack, Director � Revenue +48% 2015 � (HCF, Moneytime Health) ($2+m) Market cap of $15m

  • � 92m shares on issue � Christian Bernecker, Director � Cash consumption - <$1m � Rob Phillips, Founder and (Stream) � Gross Margins ~ 78% � Nick Schicht, General Manager �

  • CEO, holds 20% of Cash ~ $2m company

  • Uscom Annual report

New Acquisition

==> picture [220 x 92] intentionally omitted <==

==> picture [222 x 138] intentionally omitted <==

Uscom has acquired 100% of Thor Laboratories - Asthma

*

Company Overview

Uscom benefits

  • High fidelity digital Doppler spirometry devices

  • Cash flow positive, revenue of $500k

  • Established manufacturing - 15 years

  • Accredited international manufacturing

  • Global reach

  • 4 + 3 products, CE, FDA, TGA approvals

  • Reimbursement in multiple markets

  • Global distribution

  • Strong R&D and grant history

  • Technical R&D team 16 engineers

  • Partners in Home Care Asthma in the USA

  • Marketing and management

Synergy of science, operations and strategy

  • Agreement subject to DD and Uscom capital raise

Aus competitor $75m

New Products - Asthma

==> picture [77 x 102] intentionally omitted <==

Products in Market

New Products

Digital Doppler Spirometer

New – AsthmaHero

Drug delivery measure Telemetry to iPhone app Smart spacer Patient interactive

Home use

==> picture [155 x 141] intentionally omitted <==

==> picture [139 x 89] intentionally omitted <==

With Diagnostics and WIFI Digital wifi spirometer

==> picture [138 x 108] intentionally omitted <==

New - BreatheSmart

Digital wifi spirometer Remote clinical monitoring Cloud diagnosis

Professional System

Desktop with advanced software analytics

New - Whistler Neonatal Asthma diagnostic

Strategic growth

Complementary products and technology

Fluid, Sepsis & Heart Failure

  • US 1.3bn market[*]

  • CAGR of 7.6%[*]

  • CE, FDA, TGA, CFDA

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

Hypertension & Vascular Health

COPD

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

& Asthma

  • US 1.7bn market[*]

  • US 400m market[*]

  • CAGR of 11.5%[*]

  • CAGR of 6.5%[*]

  • CE, FDA, TGA

  • CE, TGA, FDA

USCOM 1A

Cardiac Output Monitoring

==> picture [190 x 195] intentionally omitted <==

Thor Pulmonary Monitoring

BP+

Blood Pressure Monitoring

==> picture [132 x 135] intentionally omitted <==

==> picture [175 x 107] intentionally omitted <==

Acquired July 2013 Aus competitor - $50m

Acquired Sept 2015 Aus competitor - $75m

  • Source: MedTech Insight; Transparency Market Research

De-Risked technology

Featured in 400+ peer reviewed publications and presentations

==> picture [98 x 117] intentionally omitted <==

==> picture [102 x 125] intentionally omitted <==

==> picture [96 x 113] intentionally omitted <==

==> picture [94 x 110] intentionally omitted <==

==> picture [93 x 111] intentionally omitted <==

==> picture [93 x 112] intentionally omitted <==

==> picture [81 x 107] intentionally omitted <==

Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia, Pulmonary hypertension, Nurse outreach, Organ procurement, Haemodialysis, Neonates, infants, Children etc……..

Uscom People - Global

Nick Schicht Steve Haken Andrew Kenig

==> picture [103 x 126] intentionally omitted <==

==> picture [100 x 126] intentionally omitted <==

==> picture [111 x 125] intentionally omitted <==

Denise Pater Tina Wu Rik Denicke

==> picture [93 x 64] intentionally omitted <==

==> picture [85 x 127] intentionally omitted <==

==> picture [104 x 125] intentionally omitted <==

==> picture [93 x 64] intentionally omitted <==

Rob Phillips

==> picture [105 x 128] intentionally omitted <==

Global Euro Aus

Global Global USA Global

Bev Jacobson Richard Scott George Tang Lindy Belleza George Ferenczi Hagay Gilad Steve Wilson

==> picture [102 x 125] intentionally omitted <==

==> picture [107 x 124] intentionally omitted <==

==> picture [94 x 126] intentionally omitted <==

Global Global Aus

==> picture [97 x 124] intentionally omitted <==

Aus

==> picture [99 x 125] intentionally omitted <==

==> picture [93 x 125] intentionally omitted <==

Global Aus

==> picture [103 x 126] intentionally omitted <==

==> picture [36 x 13] intentionally omitted <==

----- Start of picture text -----

USA
----- End of picture text -----

Current growth

Revenue and Income

==> picture [348 x 273] intentionally omitted <==

----- Start of picture text -----

$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015
----- End of picture text -----

Distribution Agreements

==> picture [342 x 254] intentionally omitted <==

----- Start of picture text -----

40 38
35
30
27
25
20
15
12
10
5
0
2013 2014 2015
----- End of picture text -----

Distribution – sales – revenue Thor acquisition adds distribution and revenue

  • FY to date

Operations growth

  1. Uscom Limited

Maintaining growth

  1. Uscom UK

  2. Uscom Budapest 4. Uscom Inc US

2 •[•] • •[• •] • •• 3

[• ] • • • • •[•] •

[•] • •

[•] •

4 •• • •• • • • • • • • • •

[•] • 1 US Focus 2016 Stephen Wilson – Former VP Corporate Development Welch Allyn appointed

Key Markets 1. AsiaPAC – 65% 2/3. Europe – 27% 4. Nth America – 8%

Revenue Targets

==> picture [653 x 397] intentionally omitted <==

----- Start of picture text -----

Thor
Total Revenue
20,000,000
18,000,000
16,000,000 BP+
14,000,000
12,000,000
Thor
$ 10,000,000
BP+
USCOM
8,000,000
USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
----- End of picture text -----*

==> picture [395 x 21] intentionally omitted <==

----- Start of picture text -----

$20m revenue by 2020 - 5 year CAGR of 58%
----- End of picture text -----

The Future

Value Cascade

==> picture [624 x 33] intentionally omitted <==

Products Sales Operations Opportunities USCOM 1A Current distribution Global operations Dividend Uscom BP+ Thor distribution Increased products Share price growth Spirotube New distribution Increased scale Transaction Otthon Completion of Major partners Cost effective CaS pi roDesktal Raise manufacture Re-imbursement BreatheSmart Revenue growth US market focus AsthmaHero Profitability ThorSoft

Products – Sales – Revenue - Opportunities

Business Risks & Mitigants

==> picture [733 x 392] intentionally omitted <==

----- Start of picture text -----

Risks Mitigants
� �
Global markets unpredictable Diversified and expanded products
� �
Competitiveness of market sectors Senior sales and marketing personnel
� �
Thor integration & key staff retention Earn outs in Thor deal structure
� �
Ongoing Thor business management Earn outs in Thor deal structure
� �
Thor distraction from USCOM & BP+ Product diversification
� �
Regulatory costs and timelines Additional focused resources
� �
Distribution & revenue growth Key Uscom and Thor staff
� �
Working capital requirements to Additional WC from capital raise
meet increased product demand
----- End of picture text -----

UCM Investment

==> picture [452 x 291] intentionally omitted <==

----- Start of picture text -----

ASX 10yr CAGR
14
12
10
8
% 6
4
2
0
Mining Financials Health BHP NAB Resmed
-2
----- End of picture text -----

UCM sales growth 2014 – 67% 2015 – 59%

Health outperforms!

*Dividend exclusive

*25[th] August

Market anomaly - opportunity

Opposing forces! Disconnect between performance and price

UCM share price

UCM Revenue and Income

==> picture [351 x 235] intentionally omitted <==

----- Start of picture text -----

$4,000,000
$3,500,000
$3,500,000
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,377,716
$1,500,000
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015 2016
----- End of picture text -----*

Unrecognised value

  • Estimate

Uscom

Value investment Strong growth phase ✓ ✓ Positioned for on going growth Strong underlying business Premium global markets Diversified and lifesaving technologies Sector leading management Aggressive global growth strategy Right time

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

==> picture [842 x 118] intentionally omitted <==

Thanks

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO